In recent years, accumulated studies have shown that FAM64A has been investigated as a prospective biomarker for various cancers, with up-regulated expression levels in breast cancer (Yao et al. 2019, Zhang et al. 2019a), pancreatic cancer (Jiao et al. 2019), lung cancer (Mizuno et al. 2020), prostate cancer (Zhou et al. 2021), osteosarcoma (Jiang et al. 2020) and colitis-associated cancer (Xu et al. 2019). Here, PIMREG is linked to breast carcinoma.